Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02044081 · ClinicalTrials.gov registry record · Phase 2
Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults
A Phase 2 study, sponsored by Armata Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT02044081 is a Phase 2 study that has completed, run by Armata Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT02044081, a Phase 2 study, has completed, sponsored by Armata Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The focus of the study is to evaluate the safety of multiple study drug administrations and the study drug selectively reducing or eliminating a specific bacteria in the mouth. It will compare a liquid and gel product applied in different modes.
Interventions
- DRUG Placebo
- DRUG C16G2 Gel
- DRUG C16G2 Rinse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02044081
The ClinicalTrials.gov registry entry for NCT02044081 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Armata Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02044081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02044081 about?
NCT02044081 is a clinical study titled "Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults". The focus of the study is to evaluate the safety of multiple study drug administrations and the study drug selectively reducing or eliminating a specific bacteria in the mouth. It will compare a liquid and gel product applied in different modes.
What is the current status of trial NCT02044081?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2014-02. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02044081?
The interventions under investigation include: Placebo (DRUG), C16G2 Gel (DRUG), C16G2 Rinse (DRUG).
Who is sponsoring clinical trial NCT02044081?
This trial is sponsored by Armata Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.